Belgium· BE-AMP-SAM663865-00
Opsumit 2.5 mg
A macitentan product containing macitentan, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 17 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Macitentan is registered in 17 of 19 countries.
Countries holding a registration under ATC C02KX04 (macitentan), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Macitentan · ATC C02KX04
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of macitentan costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Macitentan · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- IT Italy$161.10
- CH Switzerland$108.22
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Macitentan
- Manufacturer
- Janssen-Cilag International
- Country
- Belgium (BE)
- ATC code
- C02KX04
- ATC class
- Macitentan
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4860334
- be_apb7743891
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
83 interactions on record for macitentan.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Macitentan · interactions on record
83 records
- 17 severe
- 65 moderate
- 1 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ErythromycinJ01FA01severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Macitentan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandOpsumitJanssen-Cilag International NV
- United KingdomOpsumit 2.5mg dispersible tabletsJanssen-Cilag Ltd
- IrelandOpsumit 2.5 mg film-coated tabletsJanssen Pharmaceutica NV
- NetherlandsOpsumit 2,5 mg, dispergeerbare tablettenJanssen-Cilag International NV
- PolandOpsumitJanssen-Cilag International N.V.
- SwedenOpsumit 2,5 mg Dispergerbar tablettJanssen-Cilag International NV
- CzechiaMACITENTAN ACCORDAccord Healthcare S.L.U., Barcelona
- United StatesmacitentanApotex Corp.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Macepulan, Macicon
- Bulgaria · Мацитентан Зентива, Мацитентан Тева
- Cyprus · Macitentan Sandoz
- Czechia · Macitentan Olpha, Macitentan Teva
- Germany · Macitentan 1 A Pharma, Macitentan Abdi
- Denmark · Macitentan "sandoz", Macitentan Devatis
- Estonia · Macitentan Norameda, Macitentan Olpha
- Spain · Macitentan Dr. Reddys, Macitentán Glenmark
- Finland · Macitentan Devatis, Macitentan Glenmark
- France · Macitentan Olpha, Opsaren
- United Kingdom (Northern Ireland) · Macitentan, Macitentan Accord Healthcare
- Greece · Macitentan Bioars, Macitentan Pharmapath
- Croatia · Jesoxade, Macitentan Teva
- Hungary · Cidevia, Macepulan
- Ireland · Macitentan Abdi, Macitentan Clonmel
- Iceland · Macitentan Accord, Macitentan Accordpharma
- Italy · Macitentan Abdi, Macitentan Aurobindo
- Liechtenstein · Macitentan Accord, Macitentan Accordpharma
- Lithuania · Macitentan Norameda, Macitentan Olpha
- Luxembourg · Macitentan Ab, Macitentan Eg
- Latvia · Macitentan Norameda, Macitentan Olpha
- Malta · Cidevia, Macitentan Clonmel
- Netherlands · Macitentan Aurobindo, Macitentan Cf
- Norway · Macitentan Accord, Macitentan Accordpharma
- Poland · Jesoxade, Macitentan Olpha
- Portugal · Macitentan Onkogen, Macitentano
- Romania · Jesoxade, Macitentan Stada
- Sweden · Macitentan Amarox, Macitentan Bioglan
- Slovakia · Macitentan Olpha, Macitentan Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f461fe66-aca0-4d2e-b804-3cb58c29efc3 GET /v1/drugs/f461fe66-aca0-4d2e-b804-3cb58c29efc3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersible tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Opsumit 2.5 mg",
"name_fr": "Opsumit 2.5 mg",
"name_nl": "Opsumit 2.5 mg",
"amp_code": "SAM663865-00",
"strengths": [
"2.5000",
"2.5000",
"25.0000"
],
"pack_count": 1,
"substances": [
"Macitentan",
"Isomalt",
"Mannitol",
"Lactose Monohydrate",
"Sodium Starch Glycolate (Type A)",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Macitentan",
"authorisation_numbers": [
"EU/1/13/893/004"
]
}See everything about macitentan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.